HOME Top Market Reports Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-Ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) Global Trends & Forecast To 2017

Contrast Media/Contrast Agents Market By Product (Iodinated, Gadolinium & Barium), By Technique (X-Ray, CT, MRI, Cath Lab & Ultrasound) & By Application (Radiology, Interventional Radiology & Interventional Cardiology) Global Trends & Forecast To 2017

By: marketsandmarkets.com
Publishing Date: January 2013
Report Code: MD 1371

Discount on Reports  

  Speak to Analyst Enquiry Before Buying
Analyst Briefing  
purchase report
download pdf  request for customisation


Contrast media have evolved significantly over the past century, from barium and iodine-based agents that were used initially by medical practitioners and radiologists, to the more advanced agents like radiopharmaceuticals and gold nanoparticles that are currently in use. Sophisticated techniques such as targeted MRI imaging and gas microbubble technology in ultrasound will prove to be essential drivers in the widespread use of contrast agents in the future.

The global market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

The global contrast agent market, though fairly mature at present (2012), still shows potential to grow over the next five years. It is propelled by the increasing demand for diagnostic imaging and image guided surgical procedures, technological advances in diagnostic imaging and the ever-increasing incidence rates of cancer and cardiac disorders. However, a few pivotal factors affecting the growth of this market are major economies of the world undergoing healthcare reforms, thereby affecting contrast media sales and the economic slowdown restricting the overall growth of this market.

The U.S. represents the largest contrast agent market worldwide, followed by Europe and Japan. However, the economic slowdown has augmented opportunities for emerging markets like India and China to strengthen their position in the global arena. Advances in medical technology coupled with huge foreign investments from developed nations, allows these emerging markets to compete with global market leaders in this segment. Investment firms are increasingly focusing on expansion in developing markets of Asia, Latin America and Eastern Europe, since the U.S. is on the brink of embracing healthcare reforms and major economies in Europe are still recovering from huge financial deficits.

The global market place is highly competitive, with several small players specific to a particular geography challenging major ones. Owing to the recession and the emerging opportunities in developing countries, many small companies have similar product offerings at competitive prices. Some of the major players profiled in this report are GE Healthcare (U.K.), Bracco Diagnostic, Inc. (Italy), Bayer Healthcare Pharmaceuticals (Germany), Covidien (Ireland) and Guerbet Group (France).

The scope of the report spans the global contrast media market which comprises:

By Product

  • Barium-based contrast media
  • Iodinated contrast media
    • Low-osmolar contrast media (LOCM)
    • High-osmolar contrast media (HOCM)
  • Gadolinium-based contrast media

By Route of Administration

  • Oral
  • Injection
    • Intravenous (I.V.)
    • Intra-arterial (I.A.)
  • Rectal
  • Urethral

By Medical Procedure

  • X-ray
  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI)
  • Ultrasound
  • Catheterization laboratory (cath lab)

By Indication

  • Cardiovascular disorders
  • Neurological disorders
  • Gastrointestinal disorders
  • Respiratory diseases
  • Musculoskeletal anomalies
  • Nephrological disorders
  • Oncology (tumor detection)

By Application

  • Radiology
  • Interventional radiology
  • Interventional cardiology

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • United Kingdom (U.K.)
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavian countries (Sweden, Denmark, Finland,  and Norway)
    • Rest of Europe
  • Asia-Pacific (APAC)
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Rest of the world (RoW)
    • Latin America
    • Middle East & Africa
    • Russia  

Each section of the report offers market data for the various market segments and geographies. It also provides in-depth information on market trends with respect to drivers, restraints, opportunities and technology trends.

    TABLE OF CONTENTS
     
    1 INTRODUCTION
      1.1 KEY TAKE-AWAYS
      1.2 REPORT DESCRIPTION
      1.3 MARKETS COVERED
      1.4 STAKEHOLDERS
      1.5 RESEARCH METHODOLOGY
          1.5.1 MARKET SIZE
          1.5.2 MARKET SHARE
          1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
          1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES

    2 EXECUTIVE SUMMARY

    3 MARKET OVERVIEW
      3.1 INTRODUCTION
      3.2 MARKET SEGMENTATION
      3.3 MARKET DYNAMICS
          3.3.1 DRIVERS
                3.3.1.1 INCREASING DEMAND FOR DIAGNOSTIC & IMAGE GUIDED PROCEDURES INFLUENCES CONTRAST MEDIA SALES
                3.3.1.2 TECHNOLOGICAL ADVANCEMENTS TO SPUR THE CONTRAST MEDIA MARKET
                3.3.1.3 INCREASING INCIDENCE & MORTALITY OF CANCER & CARDIAC DISEASES TO BOOST GROWTH OF CONTRAST MEDIA
                3.3.1.4 GROWTH OF MEDICAL IMAGING TECHNOLOGY IN EMERGING MARKETS
          3.3.2 RESTRAINTS
                3.3.2.1 MAJOR ECONOMIES UNDERGOING HEALTHCARE REFORMS TO AFFECT THE SALES ON CONTRAST MEDIA
                3.3.2.2 ECONOMIC SLOWDOWN TO INHIBIT GROWTH
          3.3.3 OPPORTUNITIES
                3.3.3.1 GROWING INVESTMENT POTENTIAL IN IMMATURE EMERGING MARKETS
                3.3.3.2 ADVENT OF NOVEL CONTRAST AGENTS COMBINING PROPERTIES OF CONTRAST MEDIA & RADIOPHARMACEUTICALS
          3.3.4 BURNING ISSUE - TOXICITY
                3.3.4.1 NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
                3.3.4.2 CONTRAST-INDUCED NEPHROTOXICITY (CIN)
          3.3.5 TECHNOLOGY TRENDS
                3.3.5.1 N1177 A REVOLUTIONARY MACROPHAGE LABELING AGENT
                3.3.5.2 SPAGO PIX ACCURATE VISUALIZATION OF TUMORS WITH MRI
                3.3.5.3 CMC-001 FOCUSED ON LIVER MRI
      3.4 MARKET SHARE ANALYSIS

    4 BY PRODUCT
      4.1 INTRODUCTION
      4.2 BARIUM-BASED CONTRAST MEDIA
          4.2.1 TECHNICAL OVERVIEW
          4.2.2 MARKET DYNAMICS
          4.2.3 MARKET ANALYSIS
      4.3 IODINATED CONTRAST MEDIA
          4.3.1 TECHNICAL OVERVIEW
          4.3.2 MARKET DYNAMICS
          4.3.3 MARKET ANALYSIS
          4.3.4 TYPES LOW-OSMOLAR AND HIGH-OSMOLAR
                4.3.4.1 LOW-OSMOLAR CONTRAST MEDIA (LOCM)
                        4.3.4.1.1 TECHNICAL OVERVIEW
                        4.3.4.1.2 MARKET ANALYSIS
                4.3.4.2 HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
                        4.3.4.2.1 TECHNICAL OVERVIEW
                        4.3.4.2.2 MARKET ANALYSIS
      4.4 GADOLINIUM-BASED CONTRAST MEDIA
          4.4.1 TECHNICAL OVERVIEW
          4.4.2 MARKET DYNAMICS
          4.4.3 MARKET ANALYSIS

    5 BY ROUTE OF ADMINISTRATION
      5.1 INTRODUCTION
      5.2 ORAL CONTRAST MEDIA
          5.2.1 TECHNICAL OVERVIEW
          5.2.2 MARKET DYNAMICS
          5.2.3 MARKET ANALYSIS
      5.3 INJECTABLE CONTRAST MEDIA
          5.3.1 TECHNICAL OVERVIEW
          5.3.2 MARKET DYNAMICS
          5.3.3 MARKET ANALYSIS
          5.3.4 INJECTABLE CONTRAST MEDIA TYPES
                5.3.4.1 INTRAVENOUS (IV)
                5.3.4.2 INTRA-ARTERIAL (IA)
      5.4 RECTAL CONTRAST MEDIA
          5.4.1 TECHNICAL OVERVIEW
          5.4.2 MARKET DYNAMICS
          5.4.3 MARKET ANALYSIS
      5.5 URETHRAL CONTRAST MEDIA
          5.5.1 TECHNICAL OVERVIEW
          5.5.2 MARKET DYNAMICS
          5.5.3 MARKET ANALYSIS

    6 BY MEDICAL PROCEDURE
      6.1 INTRODUCTION
      6.2 X-RAY
          6.2.1 TECHNICAL OVERVIEW
          6.2.2 MARKET DYNAMICS
          6.2.3 MARKET ANALYSIS
      6.3 COMPUTED TOMOGRAPHY (CT)
          6.3.1 TECHNICAL OVERVIEW
          6.3.2 MARKET DYNAMICS
          6.3.3 MARKET ANALYSIS
      6.4 MAGNETIC RESONANCE IMAGING (MRI)
          6.4.1 TECHNICAL OVERVIEW
          6.4.2 MARKET DYNAMICS
          6.4.3 MARKET ANALYSIS
      6.5 ULTRASOUND
          6.5.1 TECHNICAL OVERVIEW
          6.5.2 MARKET DYNAMICS
          6.5.3 MARKET ANALYSIS
      6.6 CATHETERIZATION LABORATORY (CATH LAB)
          6.6.1 TECHNICAL OVERVIEW
          6.6.2 MARKET DYNAMICS
          6.6.3 MARKET ANALYSIS

    7 BY INDICATION
      7.1 INTRODUCTION
      7.2 CARDIOVASCULAR DISORDERS
          7.2.1 MARKET DYNAMICS
          7.2.2 MARKET ANALYSIS
      7.3 NEUROLOGICAL DISORDERS
          7.3.1 MARKET DYNAMICS
          7.3.2 MARKET ANALYSIS
      7.4 RESPIRATORY DISEASES
          7.4.1 MARKET DYNAMICS
          7.4.2 MARKET ANALYSIS
      7.5 GASTROINTESTINAL DISORDERS
          7.5.1 MARKET DYNAMICS
          7.5.2 MARKET ANALYSIS
      7.6 ONCOLOGY
          7.6.1 MARKET DYNAMICS
          7.6.2 MARKET ANALYSIS
      7.7 MUSCULOSKELETAL ANOMALIES
          7.7.1 MARKET DYNAMICS
          7.7.2 MARKET ANALYSIS
      7.8 NEPHROLOGICAL DISORDERS
          7.8.1 MARKET DYNAMICS
          7.8.2 MARKET ANALYSIS

    8 BY APPLICATION
      8.1 INTRODUCTION
      8.2 RADIOLOGY
          8.2.1 TECHNICAL OVERVIEW
          8.2.2 MARKET DYNAMICS
          8.2.3 MARKET ANALYSIS
      8.3 INTERVENTIONAL RADIOLOGY
          8.3.1 TECHNICAL OVERVIEW
          8.3.2 MARKET DYNAMICS
          8.3.3 MARKET ANALYSIS
      8.4 INTERVENTIONAL CARDIOLOGY
          8.4.1 TECHNICAL OVERVIEW
          8.4.2 MARKET DYNAMICS
          8.4.3 MARKET ANALYSIS

    9 GEOGRAPHIC ANALYSIS
      9.1 INTRODUCTION
      9.2 NORTH AMERICA
      9.3 EUROPE
      9.4 ASIA-PACIFIC
      9.5 REST OF THE WORLD (ROW)

    10 COMPETITIVE LANDSCAPE
       10.1 INTRODUCTION
       10.2 MERGERS & ACQUISITIONS
       10.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES
       10.4 NEW PRODUCT LAUNCH
       10.5 EXPANSION
       10.6 APPROVALS
       10.7 OTHER DEVELOPMENTS

    11 COMPANY PROFILES
       (OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, AND DEVELOPMENTS)* SNAPSHOT
       11.1 AMAG PHARMACEUTICALS, INC.
       11.2 BAYER HEALTHCARE PHARMACEUTICALS
       11.3 BRACCO IMAGING SPA (A SUBSIDIARY OF BRACCO S.P.A)
       11.4 COVIDIEN
       11.5 CMC CONTRAST AB
       11.6 DAIICHI SANKYO CO., LTD.
       11.7 GE HEALTHCARE
       11.8 GENOVIS AB
       11.9 GUERBET GROUP
       11.10 LANTHEUS MEDICAL IMAGING, INC.
       11.11 NANOPET PHARMA GMBH
       11.12 NANOSCAN IMAGING, LLC
       11.13 SANOCHEMIA PHARMAZEUTIKA AG
       11.14 SPAGO IMAGING AB (A SUBSIDIARY OF ACCELERATOR NORDIC AB)
       11.15 SUBHRA PHARMA PRIVATE, LTD
       11.16 TAEJOON PHARM CO., LTD.
       11.17 TARGESON, INC.
       11.18 UNIJULES LIFE SCIENCES, LTD.
       *DETAILS ON FINANCIALS, PRODUCT & SERVICES, STRATEGY, AND DEVELOPMENTS MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES. 
     

    LIST OF TABLES
     
    TABLE 1 GLOBAL CONTRAST MEDIA MARKET, BY PRODUCT,2010 2017 ($MILLION)
    TABLE 2 BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 3 CLASSIFICATION OF GBCAS BY U.S. FDA BASED ON NUMBER OF NSF CASES
    TABLE 4 MARKET REVENUE, BY PRODUCT,2010 - 2017 ($MILLION)
    TABLE 5 MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 6 BARIUM-BASED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010-2017 ($MILLION)
    TABLE 7 IODINATED CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 8 IODINATED MARKET REVENUE, BY TYPE,2010 - 2017 ($MILLION)
    TABLE 9 IODINATED-LOCM MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 10 IODINATED-HOCM MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 11 GADOLINIUM-BASED CONTRAST MEDIA MARKET REVENUE,BY GEOGRAPHY, 2010 - 2017 ($MILLION)
    TABLE 12 GLOBAL CONTRAST AGENT MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2010 2017 ($MILLION)
    TABLE 13 ORAL CONTRAST AGENT MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 14 INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 15 INJECTABLE MARKET REVENUE, BY TYPE,2010 2017 ($MILLION)
    TABLE 16 INTRAVENOUS INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 17 INTRA-ARTERIAL INJECTABLE MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 18 RECTAL CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 19 URETHRAL MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 20 MARKET REVENUE, BY MEDICAL PROCEDURE, 2010 2017 ($MILLION)
    TABLE 21 X-RAY - MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 22 CT - MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 23 MRI - MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 24 ULTRASOUND - MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 25 CATH LAB MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 26 GLOBAL MARKET, BY INDICATION,2010 2017 ($MILLION)
    TABLE 27 CARDIOVASCULAR DISEASES - BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 28 NEUROLOGICAL DISORDERS - BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 29 RESPIRATORY DISEASES - MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 30 GASTROINTESTINAL DISORDERS - MARKET,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 31 ONCOLOGY - BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 32 MUSCULOSKELETAL ANOMALIES BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 33 NEPHROLOGICAL DISORDERS - MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 34 MARKET REVENUE, BY APPLICATION,2010 2017 ($MILLION)
    TABLE 35 RADIOLOGY CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 36 INTERVENTIONAL RADIOLOGY MARKET REVENUE,BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 37 INTERVENTIONAL CARDIOLOGY MARKET REVENUE, BY GEOGRAPHY, 2010 2017 ($MILLION)
    TABLE 38 CONTRAST MEDIA MARKET REVENUE, BY GEOGRAPHY,2010 2017 ($MILLION)
    TABLE 39 NORTH AMERICA: CONTRAST MEDIA MARKET, BY COUNTRY,2010 2017 ($MILLION)
    TABLE 40 NORTH AMERICA: BY PRODUCT,2010 2017 ($MILLION)
    TABLE 41 NORTH AMERICA: IODINATED MARKET, BY TYPE, 2010 2017 ($MILLION)
    TABLE 42 NORTH AMERICA: BY APPLICATION,2010 2017 ($MILLION)
    TABLE 43 NORTH AMERICA: BY INDICATION,2010 2017 ($MILLION)
    TABLE 44 NORTH AMERICA: BY ROUTE OF ADMINISTRATION, 2010 2017 ($MILLION)
    TABLE 45 NORTH AMERICA: INJECTABLE CONTRAST MEDIA MARKET,BY TYPE, 2010 2017 ($MILLION)
    TABLE 46 NORTH AMERICA: BY MEDICAL PROCEDURE, 2010 2017 ($MILLION)
    TABLE 47 EUROPE: CONTRAST MEDIA MARKET, BY COUNTRY,2010 2017 ($MILLION)
    TABLE 48 EUROPE: BY PRODUCT,2010 2017 ($MILLION)
    TABLE 49 EUROPE: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 2017 ($MILLION)
    TABLE 50 EUROPE: BY APPLICATION,2010 2017 ($MILLION)
    TABLE 51 EUROPE: BY INDICATION,2010 2017 ($MILLION)
    TABLE 52 EUROPE: BY ROUTE OF ADMINISTRATION, 2010 2017 ($MILLION)
    TABLE 53 EUROPE: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 2017 ($MILLION)
    TABLE 54 EUROPE: BY MEDICAL PROCEDURE,2010 2017 ($MILLION)
    TABLE 55 APAC: CONTRAST MEDIA MARKET, BY COUNTRY,2010 2017 ($MILLION)
    TABLE 56 APAC: BY PRODUCT,2010 2017 ($MILLION)
    TABLE 57 APAC: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 2017 ($MILLION)
    TABLE 58 APAC: BY APPLICATION,2010 2017 ($MILLION)
    TABLE 59 APAC: BY INDICATION,2010 2017 ($MILLION)
    TABLE 60 APAC: BY ROUTE OF ADMINISTRATION, 2010 2017 ($MILLION)
    TABLE 61 APAC: INJECTABLE CONTRAST MEDIA MARKET, BY TYPE,2010 2017 ($MILLION)
    TABLE 62 APAC: BY MEDICAL PROCEDURE,2010 2017 ($MILLION)
    TABLE 63 ROW: REVENUE, BY REGION,2010 2017 ($MILLION)
    TABLE 64 ROW: MARKET REVENUE, BY PRODUCT,2010 2017 ($MILLION)
    TABLE 65 ROW: IODINATED CONTRAST MEDIA MARKET, BY TYPE,2010 2017 ($MILLION)
    TABLE 66 ROW: BY APPLICATION,2010 2017 ($MILLION)
    TABLE 67 ROW: BY INDICATION,2010 2017 ($MILLION)
    TABLE 68 ROW: BY ROUTE OF ADMINISTRATION, 2010 2017 ($MILLION)
    TABLE 69 ROW: INJECTABLE CONTRAST MEDIA MARKET REVENUE, BY TYPE,2010 2017 ($MILLION)
    TABLE 70 ROW: REVENUE, BY MEDICAL PROCEDURE,2010 2017 ($MILLION)
    TABLE 71 MERGERS & ACQUISITIONS, 2010 2012
    TABLE 72 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 2012
    TABLE 73 NEW PRODUCT LAUNCH, 2010 2012
    TABLE 74 EXPANSION, 2010 2012
    TABLE 75 APPROVALS, 2010 2012
    TABLE 76 OTHER DEVELOPMENTS, 2010 2012
    TABLE 77 AMAG PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES,2009 2011 ($MILLION)
    TABLE 78 AMAG PHARMACEUTICALS: TOTAL REVENUE, BY SEGMENT,2009 2011 ($MILLION)
    TABLE 79 AMAG PHARMACEUTICALS: TOTAL PRODUCT SALES, BY PRODUCT, 2009 2011 ($MILLION)
    TABLE 80 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2009 2011 ($MILLION)
    TABLE 81 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY SEGMENT, 2009 2011 ($MILLION)
    TABLE 82 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE,BY GEOGRAPHY, 2009 2011 ($MILLION)
    TABLE 83 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY DIVISION, 2009 2011 ($MILLION)
    TABLE 84 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF HEALTHCARE SEGMENT, BY GEOGRAPHY, 2009 2011 ($MILLION)
    TABLE 85 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY SEGMENT, 2009 - 2011 ($MILLION)
    TABLE 86 BAYER HEALTHCARE PHARMACEUTICALS: TOTAL REVENUE OF CONSUMER HEALTH DIVISION, BY GEOGRAPHY,2009 2011 ($MILLION)
    TABLE 87 COVIDIEN: NET SALES AND R&D EXPENSES, 2009 2011 ($MILLION)
    TABLE 88 COVIDIEN: NET SALES, BY SEGMENTS, 2009 2011 ($MILLION)
    TABLE 89 COVIDIEN: NET SALES, BY PHARMACEUTICAL PRODUCTS,2009 2011 ($MILLION)
    TABLE 90 COVIDIEN: NET SALES, BY GEOGRAPHY, 2009 2011 ($MILLION)
    TABLE 91 DAIICHI SANKYO CO., LTD.: NET SALES AND R&D EXPENSES,2009 2011 ($BILLION)
    TABLE 92 DAIICHI SANKYO CO., LTD.: NET SALES, BY GEOGRAPHY,2009 2011 ($MILLION)
    TABLE 93 GENERAL ELECTRIC: TOTAL REVENUE AND R&D EXPENSES,2009 2011 ($BILLION)
    TABLE 94 GENERAL ELECTRIC: TOTAL REVENUE, BY SEGMENTS,2009 2011 ($BILLION)
    TABLE 95 GENERAL ELECTRIC: TOTAL REVENUE, BY GEOGRAPHY,2009 2011 ($BILLION)
    TABLE 96 GENOVIS AB: TOTAL REVENUE AND R&D EXPENSES,2010 2012 ($THOU.S.ND)
    TABLE 97 GENOVIS AB: TOTAL REVENUE, BY GEOGRAPHY,2010 2012 ($THOU.S.ND)
    TABLE 98 GUERBET: TOTAL REVENUE AND R&D EXPENSES,2010 2012 ($MILLION)
    TABLE 99 GUERBET: TOTAL REVENUE, BY PRODUCTS, 2010 2012 ($MILLION)
    TABLE 100 GUERBET: TOTAL REVENUE, BY GEOGRAPHY 2010 2012 ($MILLION)
    TABLE 101 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,2009 2011 ($MILLION)
    TABLE 102 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 2011 ($MILLION)
    TABLE 103 LANTHEUS : TOTAL REVENUE, BY GEOGRAPHY,2009 2011 ($MILLION)
    TABLE 104 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE AND R&D EXPENSES, 2010 2012 ($MILLION)
    TABLE 105 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE, BY SEGMENT, 2010 2011 ($MILLION)
    TABLE 106 SANOCHEMIA PHARMAZEUTIKA AG: TOTAL REVENUE,BY GEOGRAPHY, 2010 2012 ($MILLION)
    TABLE 107 ACCELERATOR NORDIC AB: TOTAL REVENUE AND R&D EXPENSES, 2010 2012 ($THOU.S.ND)
     
     
    LIST OF FIGURES
     
    FIGURE 1 CONTRAST MEDIA MARKET, BY GEOGRAPHY, 2010 2017 ($MILLION)
    FIGURE 2 CONTRAST MEDIA MARKET SEGMENTATION
    FIGURE 3 MARKET DYNAMICS
    FIGURE 4 MARKET SHARE ANALYSIS,BY KEY PLAYERS, 2011
    FIGURE 5 CONTRAST MEDIA MARKET SEGMENTATION, BY PRODUCT
    FIGURE 6 CHEMISTRY OF LOW OSMOLAR CONTRAST MEDIA (LOCM)
    FIGURE 7 CHEMISTRY OF HIGH-OSMOLAR CONTRAST MEDIA (HOCM)
    FIGURE 8 MARKET SEGMENTATION, BY ROUTE OF ADMINISTRATION
    FIGURE 9 MARKET SEGMENTATION, BY MEDICAL PROCEDURE
    FIGURE 10 MARKET SEGMENTATION, BY INDICATION
    FIGURE 11 MARKET SEGMENTATION, BY APPLICATION
    FIGURE 12 KEY GROWTH STRATEGIES, 2010 2012
    FIGURE 13 KEY PLAYERS FOCUSING ON AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES STRATEGY, 2010 2012
    FIGURE 14 KEY PLAYERS FOCUSING ON NEW PRODUCT LAUNCH STRATEGY,2010 2012

    The global market is broadly segmented into barium-based, iodinated and gadolinium-based contrast media. These products are further categorized based on the medical procedure (X-ray, CT, MRI, ultrasound, and catheterization laboratory), route of administration (oral, injection, rectal, and urethral), medical indication (cardiovascular, respiratory, musculoskeletal, gastrointestinal, and neurology, nephrology and oncology) and finally application (radiology, interventional radiology and interventional cardiology). The global market is worth $6.2 billion in 2012, and estimated to grow at a CAGR of 6.8% to reach $8.6 billion by 2017.

    Iodinated contrast media will drive the overall growth of the market due to its applicability in various modalities like X-ray, CT, MRI scans, ultrasound and cath lab procedures. A fall is expected in the growth rate of barium-based products since certain toxicity issues of chemical peritonitis have been reported, leading to their discontinuation by major players. Iodinated contrast agent have widespread applications in medical imaging and hence, iodinated contrast media contribute the highest to this industry. This segment is expected to grow at the highest pace compared to other segments (barium-based and gadolinium-based), mainly due to its proven efficacy in diagnostic imaging and reduced toxicity issues. North America comprises of the largest market that uses these media in radiological examinations, followed by Europe. This is attributed to the fact that major players are located in these regions with easy access and extensive use of contrast agentin almost all radiological examinations.

    Contrast media have been in use in medical diagnostic procedures since mid 1950s and is a fairly mature market in 2012. Yet, it shows good potential to grow in the next five years due to technological advances in medical imaging like low-cost CT imaging and functional MRI. The ever-increasing cancer and cardiac mortality rates globally, growth of medical imaging in emerging markets, coupled with an increase in the demand for diagnostic image-guided procedures are foreseen to act as drivers for the growth of this market. However, some of the major economies in the world are undergoing healthcare reforms which bring certain restraints in terms of reimbursement of contrast agent. Also, the economic slowdown of 2008 has proved to be another decelerating factor hindering the growth of this market.

    Global Contrast Media/Contrast Agents Market, by Geography, 2012

    Contrast Media Market

    Source: Annual Reports, Press Releases, Expert Interviews, American College of Radiology (ACR), World Health Organization (WHO), European Medicines Agency (EMEA), International Society of Radiology (ISR), Radiology Society of North America (RSNA), Journal of Radiology, MnM Analysis

    Custom Market Research Services

    We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

    Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

    Connect With Us

    Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
    Live Chat Support


    US : 1-888-600-6441
    UK : 44-800-368-9399

    Search reports